Sunitinib
- OralSunitinibSutent
Mechanism of Action
- Inhibits multiple receptor tyrosine kinases involved in tumour growth, angiogenesis and metastasis.
Pharmacology
- Many off-target effects due to inhibition of multiple targets.
Clinical Use
- Indications
- Advanced renal cell carcinoma
- Gastrointestinal stromal tumour (GIST) that has failed imatinib
- Unresectable, well-differentiated pancreatic neuroendocrine tumours
- Adverse Effects
- Fatigue
- Anorexia
- Mucositis
- Hand-foot syndrome
- Cardiotoxicity - CCF, MI, thromboembolism, hypertension
- Hypothyroidism